STOCK TITAN
  1. Home
  2. Sec-filings
  3. SYRE
  4. [Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a pre-planned option exercise and share sale. On July 1, 2026, he exercised stock options covering 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in open-market transactions at weighted average prices of $87.55 and $88.37. These trades were made under a Rule 10b5-1 trading plan adopted on November 10, 2025. After the transactions, he directly holds 97,994 common shares, plus 67,476 restricted stock units that vest in 2026 and 2027 and 352,357 remaining option shares expiring in 2033.

Positive

  • None.

Negative

  • None.

Insights

Pre-planned, routine option exercise and matching sale with sizable remaining holdings.

The CFO of Spyre Therapeutics exercised options for 7,500 shares at $14.50 and sold 7,500 shares in open-market trades at weighted average prices near $88. This is a classic exercise-and-sell pattern that realizes compensation value while leaving his net share count roughly unchanged.

The filing states these sales were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the trades were pre-scheduled rather than opportunistic. Burrows still owns 97,994 common shares directly, 67,476 RSUs vesting in 2026–2027, and 352,357 option shares expiring in 2033, so his remaining equity exposure is substantial.

Because the transactions are pre-planned and maintain significant exposure, they appear routine from a compensation and liquidity perspective rather than signaling a major change in insider sentiment. Future company filings may update his equity position as additional RSUs vest or options are exercised.

Insider Burrows Scott L
Role Chief Financial Officer
Sold 7,500 shs ($658K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 7,500 $0.00 --
Exercise Common Stock 7,500 $14.50 $109K
Sale Common Stock 5,775 $87.55 $506K
Sale Common Stock 1,725 $88.37 $152K
Holdings After Transaction: Stock Option (Right to Buy) — 352,357 shares (Direct, null); Common Stock — 105,494 shares (Direct, null)
Footnotes (1)
  1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Common shares sold 7,500 shares Open-market sales on July 1, 2026
Weighted average sale price block 1 $87.55 per share Sale of 5,775 common shares
Weighted average sale price block 2 $88.37 per share Sale of 1,725 common shares
Options exercised 7,500 shares at $14.50 Stock option exercise on July 1, 2026
Common shares held after transactions 97,994 shares Direct ownership following Form 4 trades
Restricted stock units 67,476 RSUs Vest in two equal installments in 2026 and 2027
Remaining option shares 352,357 shares Stock option expiring September 1, 2033
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units ("RSUs") financial
"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) ... This option represents a right to purchase 404,857 shares of the Issuer's common stock."
reverse stock split financial
"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023)"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burrows Scott L
(Last)(First)(Middle)
221 CRESCENT STREET, BUILDING 23,
SUITE 105
(Street)
WALTHAM MASSACHUSETTS 02453
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M(1)7,500A$14.5105,494D
Common Stock07/01/2026S(1)5,775D$87.55(2)99,719D
Common Stock07/01/2026S(1)1,725D$88.37(3)97,994(4)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$14.507/01/2026M(1)7,500 (5)09/01/2033Common Stock7,500$0352,357D
Explanation of Responses:
1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
4. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Remarks:
/s/ Heidy King-Jones, as Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Spyre Therapeutics (SYRE) report for its CFO?

Spyre Therapeutics reported that CFO Scott L. Burrows exercised stock options for 7,500 common shares at $14.50 and sold 7,500 shares in open-market trades around $88 per share, under a pre-arranged Rule 10b5-1 trading plan adopted in November 2025.

How many Spyre Therapeutics (SYRE) shares did the CFO sell and at what prices?

The CFO sold 7,500 common shares of Spyre Therapeutics. One block of 5,775 shares was sold at a weighted average price of $87.55, and another 1,725 shares at a weighted average price of $88.37, across multiple trades within disclosed price ranges.

Did the Spyre Therapeutics (SYRE) CFO’s transactions occur under a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans are pre-arranged trading programs, which typically indicate routine portfolio management rather than discretionary, market-timed insider activity.

What Spyre Therapeutics (SYRE) equity does the CFO hold after these transactions?

After the reported trades, the CFO holds 97,994 common shares directly, 67,476 restricted stock units that vest in equal parts in 2026 and 2027, and stock options representing 352,357 shares of common stock, which are scheduled to vest over time and expire in 2033.

What stock option did the Spyre Therapeutics (SYRE) CFO exercise in this Form 4?

He exercised part of a stock option with a $14.50 exercise price, converting 7,500 option rights into common shares. The underlying option originally covered 404,857 shares, adjusted for a prior reverse stock split, with the remaining 352,357 shares vesting over several years until expiration in 2033.